HZD.L Share News (HZD)

Horizon Discovery awarded £0.8m contract

Research tools provider Horizon Discovery has been contracted by bio medicine group Otsuka Pharmaceutical Development Commercialisation (OPDC) for $0.8m. The Cambridge-based group has been appointed by Otsuka to perform in vitro cell line screening for clinical stage OPDC development candidates. Th

Horizon Discovery Wins Contract With Otsuka Pharmaceutical Development

Horizon Discovery Confident On Strong Full-Year On In Line First-Half

Horizon Inks Intellectual Property Licence Deal With Stanford University

Premier Foods non-exec makes show of faith

Pam Powell, a non-executive director of Premier Foods, has acquired 74,369 shares in the group one day after it warned that sales of its key brands were set to fall short of expectations this year. Powell paid 53.5p for each of the shares, spending a total of £39,787. The modest show of faith ca

DIRECTOR DEALINGS: Horizon Discovery CEO Buys 10,000 Shares

LONDON (Alliance News) - Horizon Discovery PLC Thursday said Chief Executive Officer Darrin Disley bought 10,000 shares at a price of 145 pence per share. Following this transaction, Disley's direct beneficial interest is 682,523 shares, representing 1.02% of the total issued share capital.

Horizon Discovery Gets UK Research Grant For Cancer Diagnostics

LONDON (Alliance News) - Horizon Discovery Group PLC Monday said it has been awarded a GBP360,224 research grant from the UK's Technology Strategy Board, together with life sciences testing firm LGC Ltd to develop standardisation for next-generation cancer diagnostics. Horizon said it will

Horizon Discovery Licenses Broad Institute's Gene Editing System

LONDON (Alliance News) - Horizon Discovery Group PLC said Thursday it has licensed the Broad Institute's CRISPR/Cas9 gene editing system, which is used to mutate or change genes in living cells. The Broad Institute is a research centre in the US state of Massachusetts, connected with the Ma

Numis Chief reduces stake with sale of 3m shares

Oliver Hemsley, the Chief Executive Officer of Numis, has traded in three million shares, reducing his stake by almost a quarter to 9.4m. The 270p-a-share disposal generated £8.1m. The sale comes around one month after the group posted a 59% jump in first half revenue at £51.5m. Adjusted pre-t

DIRECTOR DEALINGS: Horizon Discovery Non-Executive Buys Shares

LONDON (Alliance News) - Life science company Horizon Discovery Group PLC Wednesday said Non-Executive Director Susan Searle purchased 16,000 shares at 159.96 pence per share for her self-invested personal pension fund. Following this transaction, Searle holds 20,000 shares, which represent

Horizon Discovery Adds US Screening Business To Portfolio

LONDON (Alliance News) - Horizon Discovery Group PLC, the biotechnology company that listed on AIM earlier this year, Thursday said it had bought the CombinatoRx service business and assets from Zalicus for GBP4.7 million, a deal that will give it a revenue generating screening business supported

Horizon Inks Licence Agreement With ERS Genomics For Intellectual Property

LONDON (Alliance News) - Horizon Discovery Group PLC said Thursday that it had entered into a non-exclusive licence agreement to allow ERS Genomics Ltd access to intellectual property relating to its CRISPR/Cas9 gene editing system. Under the agreement, Horizon will be able to use the techn

Horizon Discovery signs agreement with Genomics

Biotechnology group Horizon Discovery has entered into a non-exclusive agreement with science research group ERS Genomics to access the group's gene editing system. The company will be allowed to use technology from DR. Emmanuelle Charpentier and her colleagues for a range of research applications.

Horizon Discovery Says It Has Continued To Trade Strongly Since IPO

LONDON (Alliance News) - Horizon Discovery Group PLC said Wednesday that it had continued to trade strongly since its initial public offering, after its share price closed down 5.8%. The biotechnology company said it had traded "at least in line with expectations", and that it is pursuing i

Horizon Discovery discovers warm welcome on AIM debut

Shares rose in life science research tools supplier Horizon Discovery on its first day of dealings on Thursday. Cambridge-based Horizon, which has been ranked as one of the fastest growing biotechnology companies in Europe by Deloitte, raised a gross £40m as part of its initial public offering at